Compare Cassava Sciences Inc (FLNA) vs Remitly Global Inc (RELY) Price & Performance

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

RELY stock trades at $24.42, down 5.82% over 24 hours, but maintains strong bullish technical signals with support at $24 and resistance at $26. The company demonstrates impressive fundamental momentum with Q2 2026 EPS of $0.93 beating expectations by 650% and revenue growth accelerating to 20% year-over-year. Recent initiatives include the Global Card launch and UAE licensing expansion, positioning for continued market share gains in the $800 billion remittance market.

With 92% analyst buy ratings and a $31 consensus price target implying 27% upside, RELY presents compelling growth potential. Key risks include execution challenges in new product launches and competitive pressure in digital payments. The stock's valuation at 17.56x P/E appears reasonable given 32.25% ROE and projected 16.85% net margins for 2026.